Professor Peter Braude, Emeritus Professor of Obstetrics and Gynaecology, King's College London; former director of the Stem Cell Programme and the Pre-Implantation Genetic Diagnosis Programme, Guy's and St Thomas' NHS Foundation Trust, said:
'This is a significant achievement of the team, one which we have been working towards for many years with the support of the University, our local hospital, and most importantly the Medical Research Council. We have succeeded where many substantial commercial companies have not. Many more xeno-free lines should follow, which demonstrates the validity and foresight of this and previous governments in this important endeavour.'
Dr Dusko Ilic, Senior Lecturer in Stem Cell Science at King's, said:
'I'm pleased that we have finally been able to supply the UK Stem Cell Bank with well-characterised hES cell lines for public use, and can therefore contribute to the ongoing consolidation of the UK as a leading international player in the stem cell field. In the future, patients hoping for the benefit of regenerative medicine for serious medical conditions caused by illness, injury and ageing, can expect improved progress on cures or amelioration from hES cell-based therapy.'
Dr Rob Buckle, Head of Regenerative Medicine at the MRC, said:
'The MRC is delighted that this investment into regenerative medicine research is beginning to bear fruit. The development of xeno-free hES cells lines is a major step forward in the field as it paves the way for 'gold standard' clinical-grade cell lines suitable
|Contact: Katherine Barnes|
King's College London